Structure and assembly of group B streptococcus pilus 2b backbone protein

Group B Streptococcus (GBS) is a major cause of invasive disease in infants. Like other Gram-positive bacteria, GBS uses a sortase C-catalyzed transpeptidation mechanism to generate cell surface pili from backbone and ancillary pilin precursor substrates. The three pilus types identified in GBS cont...

Full description

Saved in:
Bibliographic Details
Published inPloS one Vol. 10; no. 5; p. e0125875
Main Authors Cozzi, Roberta, Malito, Enrico, Lazzarin, Maddalena, Nuccitelli, Annalisa, Castagnetti, Andrea, Bottomley, Matthew J, Margarit, Immaculada, Maione, Domenico, Rinaudo, C Daniela
Format Journal Article
LanguageEnglish
Published United States Public Library of Science 05.05.2015
Public Library of Science (PLoS)
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Group B Streptococcus (GBS) is a major cause of invasive disease in infants. Like other Gram-positive bacteria, GBS uses a sortase C-catalyzed transpeptidation mechanism to generate cell surface pili from backbone and ancillary pilin precursor substrates. The three pilus types identified in GBS contain structural subunits that are highly immunogenic and are promising candidates for the development of a broadly-protective vaccine. Here we report the X-ray crystal structure of the backbone protein of pilus 2b (BP-2b) at 1.06Å resolution. The structure reveals a classical IgG-like fold typical of the pilin subunits of other Gram-positive bacteria. The crystallized portion of the protein (residues 185-468) encompasses domains D2 and D3 that together confer high stability to the protein due to the presence of an internal isopeptide bond within each domain. The D2+D3 region, lacking the N-terminal D1 domain, was as potent as the entire protein in conferring protection against GBS challenge in a well-established mouse model. By site-directed mutagenesis and complementation studies in GBS knock-out strains we identified the residues and motives essential for assembly of the BP-2b monomers into high-molecular weight complexes, thus providing new insights into pilus 2b polymerization.
Bibliography:Competing Interests: Most of the authors are affiliated to Novartis Vaccines and Diagnostics; RC, EM, MJB, IM, DM and CDR are employees of Novartis Vaccines. There is a pending patent application belonging to the institution, but the authors will not benefit from it (Maione D., Cozzi R., Rinaudo D., Lazzarin M., Zerbini F., Margarit Y Ros I. 2013. Pilus proteins and compositions. WO2013/124473(PCT/EP2013/053644), filed February 23, 2013 and issued August 29, 2013). There are no products in development or marketed products to declare. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.
Current address: MedImmune, Cambridge, United Kingdom
Conceived and designed the experiments: RC EM IM DM CDR. Performed the experiments: RC EM ML AN AC. Analyzed the data: RC EM ML AN AC DM CDR. Contributed reagents/materials/analysis tools: RC EM DM. Wrote the paper: RC EM MJB CDR.
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0125875